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Abstract
Background: Overexpression of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is commonly occurred
in cancers and causes radioresistance and poor prognosis. In present study, the single-chain variable antibody
fragments (scFv) targeting DNA-PKcs was developed for the application of radiosensitization in vitro and in vivo. A
humanized semisynthetic scFv library and the phage-display antibodies technology were employed to screen DNA-
PKcs scFv antibody.
Methods: DNA-PKcs epitopes were predicted and cloned. A humanized semisynthetic scFv library and the phage-
display antibodies technology were employed to screen DNA-PKcs scFv antibody. DNA damage repair was
analyzed by comet assay and immunofluorescence detection of gH2AX foci. The radiosensitization in vivo was
determined on Balb/c athymic mice transplanted tumours of HeLa cells.
Results: Four epitopes of DNA-PKcs have been predicted and expressed as the antigens, and a specific human
anti-DNA-PKcs scFv antibody gene, anti-DPK3-scFv, was obtained by screening the phage antibody library using
the DNA-PKcs peptide DPK3. The specificity of anti-DPK3-scFv was verified, in vitro. Transfection of HeLa cells with
the anti-DPK3-scFv gene resulted in an increased sensitivity to IR, decreased repair capability of DNA double-strand
breaks (DSB) detected by comet assay and immunofluorescence detection of gH2AX foci. Moreover, the kinase
activity of DNA-PKcs was inhibited by anti-DPK3-scFv, which was displayed by the decreased phosphorylation levels
of its target Akt/S473 and the autophosphorylation of DNA-PKcs on S2056 induced by radiation. Measurement of
the growth and apoptosis rates showed that anti-DPK3-scFv enhanced the sensitivity of tumours transplanted in
Balb/c athymic mice to radiation therapy.
Conclusion: The antiproliferation and radiosensitizing effects of anti-DPK3-scFv via targeting DNA-PKcs make it very
appealing for the development as a novel biological radiosensitizer for cancer therapeutic potential.
Background
Radiotherapy is one of the effective and common mea-
sures for cancer therapy. However, there are still some
drawbacks which limit the clinic application of radio-
therapy, e.g. severe side effects resulting from normal
tissues damage and radiation tolerance of cancer cells
[1]. DNA double-strand break (DSB) is a critical lesion
induced by ionizing radiation (IR) [2], and the status of
cellular DSB repair capability is closely related to the
radiosensitivity and the outcome of radiotherapy[3,4].
DNA-dependent protein kinase catalytic subunit (DNA-
PKcs) is a critical component in NHEJ pathway of DNA
DSB repair [5], and it has a serine/threonine kinase
activity to phosphorylate its downstream targets, such as
Artemis, XRCC4, as well as autophosphorylation on its
S2056 site [6,7]. Recent evidence indicates that DNA-
PKcs is frequently overexpressed in various cancers, and
increased expression or activity of DNA-PKcs is closely
associated with metastasis, poor prognosis and radiore-
sistance of cancers [1,8-13]. Depression of DNA-PKcs
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any medium, provided the original work is properly cited.not only sensitizes cells to radiation, but also results in a
decrease in cell growth rate and c-Myc protein levels
[14]. Therefore, targeting DNA-PKcs has been promised
as an effective approach for enhancing the efficiency of
cancer radiation therapy [13-16].
S e v e r a lc h e m i c a li n h i b i t o r so fD N A - P K c sh a v eb e e n
shown a radiosensitization effect in vitro, such as non-
specific PI3K inhibitors (Wortmannin, LY294002) [17],
DNA-PK inhibitors (OK-1035, NU7026) [18]. However,
the relative low specificity and/or side effects to normal
tissues have limited their clinical application. Due to
their low immunogenicity in human being, humanized
mAbs are becoming increasingly important biological
measure of cancer therapy. Development of the huma-
nized phage antibody library allows for screening single-
chain variable antibody fragment (scFv). In essence, scFv
i sas m a l lp r o t e i nm a d eu po fb o t hv a r i a b l eh e a v ya n d
light chain domains coupled by a flexible peptide linker,
and it is less immunogenic, of greater affinity, and more
easily introduced into cells than antibodies produced by
ordinary methods. Therefore, development of single-
chain antibodies is a potential therapeutic strategy for
cancer treatment. There is a report described the produc-
tion and radiosensitizing effect in vitro of a scFv antibody
against DNA-PKcs [19]. This scFv antibody was originally
generated from a hybridoma cell line expressing the mAb
18-2 antibody of DNA-PKcs. However, it is necessary to
expand this kind of study, especially to verify the efficacy
and mechanisms of the radiosensitization of this kind of
scFv molecules through the combined studies of cellular
mechanistic experiments and the pre-clinical animal
radiotherapy trial in vivo.
In this study, a specific anti-DNA-PKcs scFv antibody
has been identified by screening a humanized phage
library using purified DNA-PKcs epitopes. The gene
encoding anti-DNA-PKcs-scFv was cloned and trans-
fected into HeLa cells. HeLa cells expressing anti-DPK3-
scFv displayed an increased radiosensitivity, decreased
DNA-PKcs activity and deficient DSB repair. In addi-
tion, nude mouse xenograft tumours of HeLa cells
expressing anti-DNA-PKcs-scFv became more sensitive
to radiation therapy, indicating that anti-DNA-PKcs-
scFv has the therapeutic potential. This anti-DNA-PKcs
scFv provides a new tool for developing cancer thera-
peutic agent and the mechanistic study of DNA-PKcs in
the cellular responses to radiation.
Methods
Cell culture
HeLa-DPK3-scFv and HeLa-pcDNA cell lines were gen-
erated from HeLa cells by transfecting with a DPK3-
scFv expressing vector (pcDNA-DPK3-scFv) and the
control vector (pcDNA3.1/Myc-His (-) B), respectively.
The cells were grown in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum, at 37°C in a
humidified atmosphere of 5% CO2/95% air.
Epitope production and scFv selection from phage-
display library
The epitopes DNA-PKcs were predicted by a patent
Biosun software, which was developed by Dr. Jian-Nan
Feng from Beijing Institute of Basic Medicine, China,
based on hydrophilicity, flexibility, antigenicity, charge
distribution and other parameters. The sequence of pep-
tide DPK3 with high antigenicity and no homology with
other proteins was determined. DPK3 was amplified by
RT-PCR, cloned into pET-22b (+), and transfected into
E. coli BL21 (DE3) cells. The expressed DPK3 in E. coli
was purified and refolded.
We employed a humanized semi-synthetic scFv library
that was previously constructed in our laboratory.
Screening of the phage-display antibody libraries was
performed as previously described [20]. Briefly, the
immunotubes coated with antigen DPK3 were incubated
with the phage library (typically 10
13 cfu) at 37°C for 2
h. After washing with 0.05% Tween-PBS, the adherent
phages were eluted using elution buffer (0.1 M HCl, pH
2.2 with solid glycine containing 0.1% BSA) and neutra-
lized with 2 M Tris buffer. Eluted phages were used to
infect E. coli XL1-Blue cells, and the Helper phage VCS-
M13 (10
12 pfu) was then added and incubated at 30°C
overnight. Phage preparation and screening was
repeated 4 times. Individual ampicillin-resistant colonies
(phage clones) were selected, and the supernatants of
phage cultures were further obtained.
The positive anti-DNA-PKcs phage clones were deter-
mined by ELISA assay in the Microtiter plates (Nunc)
coated with purified DPK3 as antigen or ovalbumin (OA)
and ferritin (Fer) as negative controls. After incubation
with the above phage clones suspension, the amount of
bound phage was determined using HRP-labeled anti-
M13 antibody (Amersham Biosciences, Piscataway, NJ)
and developed by adding OPD (o-phenylenediamine).
The reaction was monitored in a Spectra Max 340 ELISA
reader (Molecular Devices, Sunnyville, CA) at 450 nm
with a reference wavelength of 650 nm.
Genetic fingerprint assay
The scFv DNA fragment of the selected phage clones
with specific anti-DPK3 activity was amplified. PCR pro-
ducts were purified and digested with Mva I at 37°C for 2
h. The diversity of scFv was analyzed by PAGE followed
by zymography and ethidium bromidine (EB) staining.
Expression and identification of soluble anti-DPK3-scFv
Positive phage clones obtained from E. coli XL1-Blue
were used to infect E. coli HB2151 non-suppressor bac-
terial strain to obtain soluble scFv. After overnight
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ments were harvested from the supernatant and peri-
plasmic space. ELISA was performed to screen for
positive anti-DPK3 scFv fragments. Microtiter plate
wells were coated with 50 μlD P K 3( 1 0μg/ml), using
OA and Fer as negative controls, and incubated with 50
μl soluble anti-DPK3 scFv for 1 h at 37°C. Then anti-V5
antibody (R961-25, Invitrogen, Carlsbad, CA) was added
for 1 h at 37°C. The amount of bound antibody was
determined using HRP-labeled anti-Fab antibodies
(I5260, Sigma) and developed by OPD.
Sequencing of anti-DPK3-scFv and construction of
eukaryotic expression vector
The scFv DNA fragment of the selected clones with spe-
cific anti-DPK3 activity was sequenced. scFv fragments
were amplified and cloned into the eukaryotic expres-
sion vector pcDNA3.1/myc-His (-) B (Invitrogen). The
vector was transfected into HeLa, and the stable cell
lines were selected with G418.
Irradiation and clonogenic survival
Cells were irradiated at room temperature using a
60Co
g-ray source at a dose rate of 1.6 Gy/min. Colony form-
ing assays were performed immediately after irradiation
by plating cells (3 × 10
2 to 1 × 10
4)i n t o6 0 - m m - d i a -
meter Petri dishes in triplicate. After 9 days of culture,
cells were fixed with methanol, stained with Giemsa
solution, and colonies (>50 cells) were counted and the
survival curves were plotted.
Comet assay and gH2AX foci detection
Comet assay and immunofluorescent g-H2AX foci
detection of DNA DSB were performed as previously
described [21].
Caspase-3/7 activity assay
Cells were collected and lysed with lysis buffer (50 mmol/
L Tris-HCl, pH 7.5, 1% Nonidet P40, 0.5% sodium deoxy-
cholate, 150 mmol/L NaCl, 1 piece of Protease inhibitor
cocktail tablet in 50 ml solution). Cell lysates containing
25 μg of protein/well were incubated for 2 h at room
temperature with Apo-ONE® Caspase-3/7 Reagent
(G7790, Promega, Madison, WI). The fluorescence of
each well was measured using a 96-well fluorescence
plate reader at an excitation wavelength of 485 nm and
an emission wavelength of 538 nm. Data were expressed
as arbitrary units of fluorescence per microgram of pro-
tein (F/mg protein). The average level of F/mg protein
was calculated from three independent experiments.
DNA-PKcs activity detection
DNA-PKcs activity was detected using the Signa-TECT®
DNA-Dependent Protein Kinase Assay System (Promega),
in which a DNA-PK biotinylated p53-derived peptide acts
as the substrate of DNA-PKcs. The nuclear proteins were
extracted from HeLa cells, HeLa-pcDNA cells or HeLa-
DPK3-scFv cells 30 min after 4 Gy irradiation or control.
Following the manufacturer’s protocol, reaction mixtures
(25 μl) contained 6 μg of nuclear proteins from HeLa cells,
HeLa-pcDNA cells, or HeLa-DPK3-scFv cells, DNA-PK
activation buffer, reaction buffer, and 0.5 mCi [g-
32P]ATP.
Samples were incubated at 30°C for 10 min. Termination
buffer was then added and 10 μl of each reaction mixture
was spotted onto SAM2® capture membrane. After wash-
ing with 2 M NaCl, membranes were dried and subjected
to the quantification of the activities of incorporated
32P-phosphorylated substrate by Molecular Dynamics
Phosphoimager System.
Immunohybridization analysis
The antibodies used in this study were purchased com-
mercially: anti-Akt (#9271, Cell signal, Danvers, MA),
anti-phospho-Akt (Ser473, #9271, Cell signal, Danvers),
anti DNA-PKcs (phospho S2056) antibody (ab18192,
Abcam, MA), anti-DNA-PKcs antibody (H-163, Santa
C r u z ,C A ) ,a n t i - b-actin (I-19-R, Santa Cruz). Immuno-
hybridization analysis was performed as previously
described [22].
Antitumour activity in vivo
The female athymic mice (Balb/c, nu/nu) were obtained
from the Laboratory Animal Center (Beijing, China).
The Institutional Animal Licensing Committee has
approved the animal experiment undertaken, and the
research protocol was in accordance with the institu-
tional guidelines of the Animal Care and Use Commit-
tee. HeLa-pcDNA and HeLa-DPK3-scFv cells of 10
7
cells resuspended in 200 μl of DMEM were subcuta-
neously injected in the lateral back region. Once
tumours had reached a volume of about 300 mm
3,m i c e
were randomly placed into the non-irradiation (control)
or irradiation group (+ IR). Tumours in treated mice
were irradiated 2 Gy once every other day with total of
10 Gy, while the rest of the body was shielded with lead
brick. Serial measurements of tumour diameter were
made with calipers after each irradiation. Tumour
volume = width
2 × length/2.
Immunohistochemistry and TUNEL assay
Tumour tissue was dissected from euthanized nude mice,
immediately fixed in formalin and embedded in paraffin.
Sections were de-paraffinized by heating to 60°C followed
by xylene immersion and re-hydrated with sequential
ethanol submersion. Endogenous catalase activity was
eliminated with 3% H2O2 and sections were blocked and
incubated with anti-cleaved caspase-3 antibody (9661, Cell
Signaling Technology) at a dilution of 1:50 at 4°C
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Biotin Complex (SABC). The terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling
(TUNEL) assay was also performed using the In Situ Cell
Death Detection Kit, POD (11684817910, Roche, Indiana-
polis, IN). Positive staining was analyzed with the Mias
2000 Imaging Analysis System.
Statistics
Data are presented as mean ± SD. Statistical analyses of
data were carried out using Student’s t-test. P <0 . 0 5
was considered to be statistical significant. One-way
analysis of variance (ANOVA) was used to compare the
groups of the in vivo animal radiotherapy experiments
followed by the Student-Newman-Keuls method for
multiple comparisons.
Results
Identification of antigen fragment of DNA-PKcs
DNA-PKcs is approximately 470 kD consisting of 4128
amino acids. Its C-terminus contains a serine/threonine
protein kinase domain (3719- 4128) [23]. For screening
the specific anti-DNA-PKcs scFv from the phage library,
6 epitopes of DNA-PKcs have been predicted as the
antigens. DPK5 and DPK6 peptides are located in the
focal adhesion targeting (FAT) domain, which is homo-
logous with other members of the PIKK family [24], so
they were rejected. The DPK1 and DPK2 peptides are
located in the N-terminus of DNA-PKcs, and DPK3 and
DPK4 between the leucine zipper and the autopho-
sphorylation cluster (Figure 1A). The cDNA encoding
these peptides were cloned, and the peptides were
expressed in and purified from the infected Ec o l icells.
Upon inclusion body protein degeneration and refolding,
we have finally successfully obtained the soluble DPK3
peptide of ~30 kD with the purity of >95%.
Identification of the positive phage clones of scFv
antibody
Following 4 rounds of selection using a human phage-
display antibody library, 56 clones bound to DPK3 were
obtained, and 26 positive clones were confirmed by
ELISA. Clones were considered positive only if they did
not bind to negative ovalbumin and ferritin control and
Figure 1 Screening and characterization of positive phage clones of anti-DNA-PKcs segments scFv. (A) Conserved functional domains of
DNA-PKcs and the location of segments identified with epitopes predicted in DNA-PKcs. DPK1, DPK2 are located at the N-terminus of DNA-PKcs,
and DPK3 and DPK4 are located between the leucine zipper (LZ) and T2609 autophosphorylation cluster. The DPK3 segment includes Ser2056
autophosphorylation cluster. (B) PAGE electrophoresis patterns of the Mva I-digested positive anti-DPK3-scFv clones. (C) Coomassie brilliant blue
stained gel of the SDS-PAGE analysis of 10 μg purified DPK3 (~30 kD) and DPK4 (~32 kD) segments. (D) Immunohybridization (western blotting)
analysis of purified DPK3 (30 kD) and DPK4 (32 kD) segments using anti-DPK3-scFv-2 antibody. (E) Immunohybridization analysis of DNA-PKcs in
HeLa cell protein lysate using anti-DPK3-scFv-2 and anti-DNA-PKcs antibodies.
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restriction maps of five clones were shown in Figure 1B.
Non-suppressive Ec o l iHB2151 bacteria cells were
transduced with positive clones to obtain soluble scFv.
Competition test of ELISA indicated that the soluble
anti-DPK3-scFv-2 in Figure 1B showed a highest specifi-
city of antibody. The sequence data shown in Figure 2
demonstrate that its variable heavy (VH) and light chain
(VL) belong to VH4 sub-group and VL2 sub-group,
respectively. The specificity of anti-DPK3-scFv encoded
by DPK3-scFv-2 gene was further validated, which
immunohybridizes with the purified DPK3, but not
DPK4 (Figure 1C &1D). In addition, immunohybridiza-
tion analysis of total extract of HeLa cells using anti-
DPK3-scFv-2 also showed an unique immunobinding
band with DNA-PKcs as comparable with the commer-
cial rabbit polyclonal anti-DNA-PKcs antibody (Figure
1E), suggesting no cross immunoblotting reactivity with
HeLa cell extracts. Therefore, anti-DPK3-scFv-2/gene
was chosen for further studies.
Expression of anti-DPK3-scFv sensitizes HeLa cells to
radiation
HeLa-DPK3-scFv cell clones (C1 to C5) were generated
from HeLa cells stably transfected with His-tagged anti-
DPK3-scFv-2 gene and the expression level of anti-
DPK3-scFv in each clone was shown in Figure 3A. The
growth rate of the anti-DPK3-scFv-transfected cells
(HeLa-DPK3-scFv) is lightly slower as compared with
HeLa cells or the cells transfected with the mock vector
(HeLa-pcDNA) (Figure 3B), but this growth difference is
not statistically significant. There is no different in cell
cycle distribution among these three cell lines under
normal growing conditions (data not shown). Survival
assay of 4 Gy-irradiated cells determined that anti-
DPK3-scFv-transfected cells were more sensitive to g-ray
compared to control cells, with the HeLa-DPK3-scFv-c2
(clone 2) being the most sensitive clone (Figure 3C).
Clonogenic assay was further performed for the cells
after 0 - 8 Gy g-ray irradiation. Cell survival curves
demonstrate an increased radiosensitivity for the HeLa-
DPK3-scFv cells (clone 2) (Figure 3D). There was
approximately a 20% dose reduction required for the
same level of survival.
A ss h o w ni nF i g u r e3 E ,c a s p a s e - 3a c t i v i t yw a s
increased in all cell lines post-irradiation, while the
activity was relative higher in HeLa-DPK3-scFv cells
compared to HeLa and HeLa-pcDNA cells, implying
that anti-DPK3-scFv antibody increases the induction of
apoptosis by radiation.
Anti-DPK3-scFv decreases DNA-PKcs activity responding
to radiation
The expression of DNA-PKcs in anti-DPK3-scFv expres-
sing cells was determined by Western blot analysis.
Result shows that anti-DPK3-scFv does not affect the
expression of DNA-PKcs (Figure 4A). The effect of anti-
DPK3-scFv on DNA-PK activity in vitro was assayed, by
monitoring the ability of the nuclear extract from the
treated cells to phosphorylate the DNA-PK-specific
Figure 2 The Sequence of the anti-DPK2-scFv-2. The green colour and the red colour is the sequence of variable light chain (VL) and variable
heavy (VH), respectively. The blue colour is the linker.
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32P] ATP. As shown in Figure
4B, the activity of DNA-PK induced by 4 Gy irradiation
was greatly abolished in the HeLa-DPK3-scFv cells as
compared with HeLa cells and HeLa-pcDNA cells. Akt
is an anti-apoptotic factor that is phosphorylated at Ser-
473 by the activated DNA-PKcs [25]. After 4Gy g-irra-
diation, the phosphorylated Akt/S473 increased signifi-
cantly in the HeLa and HeLa-pcDNA cells, but scarcely
in HeLa-DPK3-scFv cells (Figure 4C &4D). DNA-PKcs
pS2056 is an autophosphorylated site of DNA-PKcs, and
it is included in the fragment of DPK3 (AA1960-2227).
After 8Gy g-irradiation, the phosphorylated DNA-PKcs
at S2056 remarkably increased in the control HeLa and
HeLa-pcDNA cells. However, this radiation-induced
autophosphorylation was largely abrogated in HeLa-
DPK3-scFv cells (Figure 4E &4F). These results indicate
that anti-DPK3-scFv decreases the activity of DNA-PKcs
in response to radiation.
Anti-DPK3-scFv decreases DNA double-strand break
repair (DSBR)
Neutral comet assay was performed to determine the
efficiency of DSBR. The comet tail of HeLa-DPK3-scF
cells was much longer than that of HeLa and HeLa-
pcDNA cells after 4Gy g-ray radiation (Figure 5A). Resi-
dual DNA damage in HeLa-DPK3-scFv cells was signifi-
cantly higher than that of HeLa and HeLa-pcDNA cells
0.25 h to 4 h of post-irradiation (Figure 5B).
The kinetics of g-H2AX foci induction and elimination
was measured in 1Gy g-ray irradiated cells by immuno-
fluorescence assay (Figure 5C &5D). Results demon-
strated that the residual number of g-H2AX foci per
nucleus in HeLa-DPK3-scFv cells was significantly
higher than that of HeLa and HeLa-pcDNA cells 0.5 h
to 4 h post-irradiation. These data further indicate that
anti-DPK3-scFv results in deficiency of DNA DSB repair
in HeLa-DPK3-scF cells.
Figure 3 Effect of anti-DPK3-scFv on cellular survival. (A) Immunohybridization analysis of anti-DPK3-scFv expression in HeLa cell clones (C1 -
C5) stably transfected with His-anti-DPK3-scFv-2 using an anti-His antibody. (B) Growth rates for HeLa, HeLa-pcDNA and DPK3-scFv-2-transfected
HeLa cells (HeLa-DPK3-scFv) under normal growing condition. (C) Clonogenic assays of cells survivals for HeLa, HeLa-pcDNA and the clones
(scFv-C3, C4, C5) of DPK3-scFv-2-transfected HeLa cells after 4 Gy g-ray irradiation. * P < 0.05,
#P < 0.01 as compared with control HeLa-pcDNA
cells. (D) Cell survival curves of HeLa, HeLa-pcDNA and HeLa-DPK3-scFv cells (clone 2) post-irradiation. (E) Caspase-3 activity assays of HeLa, HeLa-
pcDNA and HeLa-DPK3-scFv cells post-4 Gy irradiation. * P < 0.05 as compared with control HeLa or HeLa-pcDNA cells.
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mice
To investigate the potential for combined anti-DPK3-
scFv gene therapy and irradiation therapy, in vivo,
HeLa-pcDNA and HeLa-DPK3-scFv cells were trans-
planted into athymic mice. Xenografts were irradiated as
described in materials and methods. Result shows that
anti-DPK3-scFv largely attenuated the growth rate of
the tumours generated from HeLa-DPK3-scFv cells after
the radiotherapy (Table 1). Detection of cleaved cas-
pase-3 (Figure 6A &6B) and TUNEL assay (Figure 6C
&6D) in tumour tissue sections shows that the radia-
tion-induced apoptosis in HeLa-DPK3-scFv xenografts
was much higher than HeLa-pcDNA xenografts. These
data demonstrate that anti-DPK3-scFv enhances the
sensitivity of tumours to radiotherapy.
Discussion
In this study, a specific scFv antibody against DNA-PKcs
(anti-DPK3-scFv) has been identified by screening a
phage library using a purified DNA-PKcs fragment
(DPK3, AA1960 - 2227) as antigen. Expression of anti-
DPK3-scFv in HeLa cells increased the radiosensitivity,
and resulted in a deficient of DNA DSB repair. In addi-
tion, tumour xenografts generated from HeLa cells
expressing anti-DPK3-scFv exhibited increased radiosen-
sitivity. These observations demonstrated that anti-
DPK3-scFv is a potential effective radiosensitizer for
cancer radiotherapy.
Antibodies have been proven effective in inhibiting the
function of proteins by blocking the activity domain or
critical protein interaction sites. There have been
numerous antibody drugs undergoing pre-clinical and
Figure 4 The effects of anti-DPK3-scFv on DNA-PKcs activity. (A) Immunohybridization analysis of total DNA-PKcs protein level in HeLa,
HeLa-pcDNA and HeLa-DPK3-scFv cells. (B) In vitro detection of 4 Gy-induced DNA-PKcs activity using the Signa-TECT® DNA-Dependent Protein
Kinase Assay System. Immunoblotting pattern (C) and relative p-Akt level (the ratio of p-Akt/Akt signals) (D) of Akt, p-Akt/S473 in HeLa, HeLa-
pcDNA and HeLa-DPK3-scFv cells post-4 Gy irradiation. Immunoblotting pattern (E) and relative p-DNA-PKcs level (the ratio of p-DNA-PKcs/DNA-
PKcs signals) (F) of DNA-PKcs, p-DNA-PKcs/S2056 in HeLa, HeLa-pcDNA and HeLa-DPK3-scFv cells post-8 Gy irradiation.
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Page 7 of 11Figure 5 The effects of anti-DPK3-scFv on DNA double-strand breaks repair. (A) The comet images detected by neutral single-cell gel
electrophoresis (SCGE). (B) DNA DSB and repair expressed as the comet tail moment of SCGE assays in HeLa, HeLa-pcDNA and HeLa-DPK3-scFv
cells at given times post-4 Gy irradiation. The data are means and standard deviation from three independent experiments. * P < 0.05 as
compared with parental HeLa cells and control cells at the same time point. (C) Immunofluorescence detection of g-H2AX foci in the cells 0.5 h
to 4 h post-irradiation. (D) The residual number of g-H2AX foci per nucleus in the cells 0.5 h to 4 h post-irradiation. * P < 0.05 as compared with
parental HeLa cells and control cells at the same time point.
Table 1 Sensitization of DPK3-scFv on tumours in nude mice to radiotherapy.*
Treatment groups
+ IR (irradiation)
Tumour volume (mm
3)
(The time from the beginning of radiotherapy, day)
024681 0
bpcDNA 348.9 ± 183.0 487.5 ± 223.0 726.3 ± 252.1 808.7 ± 265.9 829.7 ± 279.9 929.2 ± 338.7
(n = 10)
# (n = 10) (n = 10) (n = 9) (n = 9) (n = 6)
pcDNA + IR 317.8 ± 127.2 520.4 ± 218.5 720.8 ± 361.4 840.4 ± 381.8 776.5 ± 193.5 757.1 ± 266.7
(n = 11) (n = 11) (n = 11) (n = 11) (n = 11) (n = 10)
DPK3-scFv 391.4 ± 213.6 531.7 ± 258.5 730.6 ± 394.4 831.3 ± 399.7 861.2 ± 331.1 938.0 ± 273.7
(n = 13) (n = 13) (n = 13) (n = 11) (n = 11) (n = 10)
DPK3-scFv + IR 394.8 ± 216.9 581.6 ± 408.5 621.4 ± 323.2 613.6 ± 282.9 521.9 ± 266.1
$ 572.7 ± 363.9
@
(n = 10) (n = 10) (n = 10) (n = 10) (n = 9) (n = 8)
* HeLa-pcDNA (control) and HeLa-DPK3-scFv cells were transplanted into athymic nude mice. Radiotherapy was performed with 60 Co g-rays as described in the
materials and methods, and tumour sizes were measured after each irradiation (+ IR) or at the same time for the non-irradiated tumours. The data are the means
± SD. One-way analysis of variance (ANOVA) was used for the statistical significant analysis.
# The animal number (n). There were 10 to 13 mice for different group at the beginning of the radiotherapy, and there occurred animal death from the sixth day
after the beginning of radiotherapy.
$ p = 0.02, 0.044, 0.035 as compared with the group pcDNA, pcDNA + IR and DPK-scFv at the same day (day 8), respectively.
@ p = 0.039, 0.017 as compared with the group pcDNA and DPK-scFv at the same day (day 10), respectively.
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this study, epitope prediction has been done prior to
screening phage display for anti-DNA-PKcs-scFv. Inter-
estingly, the DPK3 segment (AA1960-2227), that was
predicted a high antigenicity in this study, harbors the
antigen epitope of the anti-DNA-PKcs-scFv 18-2 anti-
body generated by Li et al [19]. In their study, scFv 18-2
was reversely amplified from the mRNA extracted from
the hybridoma cells expressing mAb 18-2 antibody,
and its epitope was mapped to a fragment spanning
DNA-PKcs residues 1734-2228. The scFv18-2 was
demonstrated a similar inhibiting effect as the parental
mAb on the kinase and DNA end joining activities of
DNA-PKcs in cell-free systems. Microinjection of puri-
fied scFv18-2 protein sensitized human skin melanoma
SK-MEL-28 cells to radiation and decreased DNA repair
capability. Both the scFv antibodies described in the
study and in previous report [19] verified that scFv anti-
body against DNA-PKcs is an appealing biological mea-
sure of radiosensitization. Differently, anti DPK3-scFv
Figure 6 The effect of anti-DPK3-scFv on apoptosis induction of the xenografted cancer cells in nude mice by irradiation.( A )
Immunohistochemistry staining of cleaved caspase-3 in the xenografted tumour tissue sections either non-irradiated or 3 days after the
radiotherapy. (B) Expression level of cleaved Caspase-3 in xenografted tumour tissue sections. (C) TUNEL staining of the xenografted tumour
sections either non-irradiated or 3 days after the radiotherapy. (D) Apoptosis induction measured from the TUNEL staining of xenografted
tumour tissue sections. Expression levels of the detected proteins were expressed as the percentage of positive staining cells. 100 cells were
scored for each staining. * P < 0.05 as compared with the tissues of HeLa -pcDNA xenografted tumours.
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Page 9 of 11was obtained by screening a human phage-display
library, so it has lower immunogenicity than antibodies
generated through other methods. The sequence and
molecular structure of DPK3-scFv are clear, and it can
be produced in infinity. In addition, soluble anti-DPK3-
svFv was shown to have high specificity for DNA-PKcs
in vitro. In this study, expression of anti-DPK3-scFv in
HeLa cells increased radiosensitivity, and inhibited
D S B R .I na d d i t i o n ,D N A - P Kcs associated AKT phos-
phorylation at S473 and its autophosphorylation at
S2056 induced by ionizing radiation was inhibited, and
apoptosis was increased in cells expressing anti-DPK3-
scFv. Finally, xenografts tumours expressing anti-DPK3-
scFv exhibited increased radiosensitivity. Collectively,
these data indicate that anti-DPK3-scFv owns the fea-
tures of a biological radiosensitizer by targeting DNA-
PKcs.
It is likely that the extent of radiosensitization by anti-
DPK3-scFv is relative modest as compared with the
DNA-PKcs chemical inhibitors or knockout of DNA-
PKcs. Unlike the chemical inhibitors of DNA-PKcs,
anti-DPK3-scFv does not directly target the C-terminal
conserved kinase domain. As a gene product, DPK3-
scFv approach may have also some limitations for the
application on cancers radiosensitization. The biological
activity of DPK3-scFv is largely dependent on the
expression level, half-life time, and its accessible to the
target protein. In addition, chemical modification of the
epitope may also affect on the binding of DPK3-scFv
with DNA-PKcs.
The phosphorylation of DNA-PKcs is necessary for
DNA double-strand break (DSB) repair[27]. A phos-
phorylation cluster is located in the epitope DPK3 (Fig-
ure 1A) or the binding domain of DPK3-scFv, it is
reasonable that DPK3-scFv can directly interfere the
phosphorylations of DNA-PKcs, including site of S2056,
which, in some extent, results in a deficient of DSB
repair. Although the phosphorylation of epitope may
affect the binding of DPK3-scFV with DNA-PKcs,
DPK3-scFv can actually bind to the non-phosphorylated
epitope/DNA-PKcs before the induction of DNA
damage by IR, which result in an interference/blockage
on the IR-induced phosphorylation of DNA-PKcs. This
mechanistic action is unique for DPK3-scFv. Boskovic et
a lh a v es h o w nt h a tu p o ni n c u b a t i o nw i t hD N A ,D N A -
PKcs undergoes a conformational change that activates
its kinase activity [28]. Anti-DPK3-scFv does not affect
the total expression level of DNA-PKcs protein, so the
mechanism of inhibition might involve either hindrance
of some essential interaction sites of DNA-PKcs with its
functional counterparts or blockage of a conformational
change required for progression of the end joining reac-
tion. Actually, DPK3 contains the autophosphorylation
cluster around S2056, which has been proven to be
associated with DSBR [7]. Therefore, the binding of
DPK3-scFV with DNA-PKcs may competitively block
the radiation-induced autophosphorylation DNA-PKcs
on S2056. As the detail function of this domain is
unclear, anti-DPK3-scFv would be also a good tool for
future mechanism study of DNA-PKcs function.
Conclusions
By using a human semisynthetic scFv library and the
phage-display antibodies technology, we have obtained a
DNA-PKcs specific scFv antibody, and which was shown
to sensitize cancer cells to ionizing radiation in vitro
and in vivo. Radiosensitization by this scFv antibody is
association with the decrease of DSBR capability and
partial inhibition of DNA-PKcs kinase activity. These
data suggest that anti-DNA-PKcs scFv antibody provides
a new strategy to improve therapeutic gain for radiation
therapy.
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